Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 3;8(68):112516-112529.
doi: 10.18632/oncotarget.22367. eCollection 2017 Dec 22.

Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas

Shuangshuang Fu  1 , Michael Wang  2 , David R Lairson  3 , Ruosha Li  4 , Bo Zhao  5 , Xianglin L Du  1
Affiliations

Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas

Shuangshuang Fu et al. Oncotarget. .

Abstract

Background: Few studies have assessed mantle cell lymphoma (MCL) incidence trends in the U.S. National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) areas. Previous studies were 5 to 9 years old and MCL incidence in Texas remains unknown. This study updated the temporal trends and variations of MCL incidence in the SEER areas and compared them with counterpart data in Texas.

Results: From 1995 to 2013, there were 2, 435 and 5, 193 newly diagnosed MCL patients in Texas and SEER areas. Age-adjusted MCL incidence was 0.91 per 100,000 persons per year in Texas and 1.01 in SEER areas. MCL incidence increased steadily with an annual percent change (APC) of 2.56% in SEER areas and an APC of 2.16% in Texas. In SEER areas, APCs for MCL incidence were significantly different from zero in patients with advanced stage tumor (3.33%), male (2.71%), elderly patients ≥ 80 years old (4.21%) and non-Hispanic white patients (2.83%) (all P < 0.05). Similar patterns were found in Texas for both incidence rates and APCs.

Materials and methods: We identified all adult patients with newly diagnosed MCL in Texas Cancer Registry and SEER databases from 1995 to 2013. Age-adjusted incidence rates were calculated and negative binomial regression model was used to assess the factors associated with MCL incidence.

Conclusions: MCL incidence rates increased over time in both Texas and SEER areas, with increases being greater in male, non-Hispanic white, and elderly patient ≥70 years with advanced stage tumors. Texas has similar MCL incidence trends and disparities as the national SEER areas.

Keywords: SEER; Texas; disparity; incidence; mantle cell lymphoma.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST None.

Figures

Figure 1
Figure 1. MCL age-adjusted incidence rates over time, 1995–2013
Figure 2
Figure 2. MCL age-adjusted incidence rates over time by tumor stage, 1995–2013
(A) Texas. (B) SEER.
Figure 3
Figure 3. MCL age-adjusted incidence trends by sex, 1995–2013
(A) Texas. (B) SEER.
Figure 4
Figure 4. MCL age-adjusted incidence trends by age group, 1995–2013
(A) Texas. (B) SEER.
Figure 5
Figure 5. MCL age-adjusted incidence trends by race/ethnicity, 1995–2013
(A) Texas. (B) SEER.
Figure 6
Figure 6. Kaplan-Meier survival estimates for SEER and TCR
Figure 7
Figure 7. Cumulative incidence of MCL death for SEER and TCR areas over calendar period of diagnosis
Figure 8
Figure 8. Cumulative incidence of MCL death for SEER and TCR areas by tumor stage
See this image and copyright information in PMC

References

    1. Cancer Stat Facts: Non-Hodgkin Lymphoma Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. 2017 Available from: https://seer.cancer.gov/statfacts/html/nhl.html.
    1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909–18. - PubMed
    1. Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB, Kwak L, Yi Q, Du XL, Wang M. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008;113:791–8. - PubMed
    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Fourth ed. Lyon, France: International Agency for Research on Cancer;; 2008.
    1. Vose JM. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2015;90:739–45. - PubMed